Building on work at MIT’s Koch Institute of Integrative Cancer Research, Elicio hopes to begin patient studies in 2020 for pancreatic, colorectal, head and neck cancers.
Elicio Therapeutics, a US-based developer of immunotherapies and vaccines for cancer spun out of Massachusetts Institute of Technology (MIT), officially launched yesterday with $30m in financing from undisclosed investors.
Elicio aims to commercialise effective vaccines and immunotherapies for a range of aggressive solid and blood cancers through its Amphiphile platform, which uncovers pathways for immunogens into the lymphatic system that could enhance the patient’s immune response against cancerous cells.
The spinout has already conducted preclinical studies in vivo…
